Organon (OGN) announced on Friday that its supplemental new drug application for Nexplanon has received approval from the US Food and Drug Administration, extending the use to up to five years from three years previously.
Nexplanon is indicated for use by women of reproductive potential to prevent pregnancy, according to the company.
There were no reported pregnancies and no new safety findings during the clinical study evaluating the safety and efficacy of extended use, Organon said.
Shares of the company were down 1.9% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments